全文获取类型
收费全文 | 38615篇 |
免费 | 3010篇 |
国内免费 | 140篇 |
专业分类
耳鼻咽喉 | 457篇 |
儿科学 | 1061篇 |
妇产科学 | 610篇 |
基础医学 | 4467篇 |
口腔科学 | 620篇 |
临床医学 | 4128篇 |
内科学 | 8582篇 |
皮肤病学 | 598篇 |
神经病学 | 3644篇 |
特种医学 | 1212篇 |
外国民族医学 | 2篇 |
外科学 | 6552篇 |
综合类 | 729篇 |
一般理论 | 42篇 |
预防医学 | 3113篇 |
眼科学 | 945篇 |
药学 | 2427篇 |
中国医学 | 45篇 |
肿瘤学 | 2531篇 |
出版年
2023年 | 273篇 |
2022年 | 494篇 |
2021年 | 1224篇 |
2020年 | 654篇 |
2019年 | 1010篇 |
2018年 | 1159篇 |
2017年 | 794篇 |
2016年 | 806篇 |
2015年 | 995篇 |
2014年 | 1379篇 |
2013年 | 1784篇 |
2012年 | 2730篇 |
2011年 | 2689篇 |
2010年 | 1495篇 |
2009年 | 1281篇 |
2008年 | 2186篇 |
2007年 | 2239篇 |
2006年 | 2123篇 |
2005年 | 2012篇 |
2004年 | 1855篇 |
2003年 | 1706篇 |
2002年 | 1558篇 |
2001年 | 428篇 |
2000年 | 374篇 |
1999年 | 415篇 |
1998年 | 346篇 |
1997年 | 287篇 |
1996年 | 293篇 |
1995年 | 232篇 |
1994年 | 202篇 |
1993年 | 198篇 |
1992年 | 283篇 |
1991年 | 248篇 |
1990年 | 285篇 |
1989年 | 225篇 |
1988年 | 245篇 |
1987年 | 232篇 |
1986年 | 224篇 |
1985年 | 228篇 |
1984年 | 235篇 |
1983年 | 228篇 |
1982年 | 242篇 |
1981年 | 229篇 |
1980年 | 235篇 |
1979年 | 235篇 |
1978年 | 186篇 |
1977年 | 143篇 |
1976年 | 159篇 |
1974年 | 162篇 |
1973年 | 136篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
6.
Anuj Shrestha Zeeshan Jawa Kathryn L. Koch Amy B. Rankin Qun Xiang Anand Padmanabhan Matthew S. Karafin Joshua J. Field 《Journal of clinical apheresis》2015,30(6):353-358
Red cell exchange (RCE) is a common procedure in adults with sickle cell disease (SCD). Implantable dual lumen Vortex (DLV) ports can be used for RCE in patients with poor peripheral venous access. We performed a retrospective cohort study of RCE procedures performed in adults with SCD. The main objective of the study was to compare the inlet speed, duration of procedures and rate of complications performed through DLV ports to those performed through temporary central venous and peripheral catheters. Twenty‐nine adults with SCD underwent a total of 318 RCE procedures. Twenty adults had DLV ports placed and 218 procedures were performed using DLV ports. Mean length of follow‐up after DLV port placement was 397 ± 263 days. Six DLV ports were removed due to infection and 1 for malfunction after a mean of 171 ± 120 days. Compared to temporary central venous and peripheral catheters, DLV port procedures had a greater rate of procedural complications, a longer duration, and a lower inlet speed (all P < 0.01). When accounting for the maximum allowable inlet speed to avoid citrate toxicity, 40% of DLV port procedures were greater than 10% below maximum speed, compared to 7 and 14% of procedures performed through temporary central venous and peripheral catheters (P < 0.0001). In conclusion, DLV ports can be used for RCE in adults with SCD, albeit with more procedural complications and longer duration. The smaller internal diameter and longer catheter of DLV ports compared to temporary central venous catheters likely accounts for the differences noted. J. Clin. Apheresis 30:353–358, 2015. © 2015 Wiley Periodicals, Inc. 相似文献
7.
8.
Geneticists have, for years, understood the nature of genome‐wide association studies using common genomic variants. Recently, however, focus has shifted to the analysis of rare variants. This presents potential problems for researchers, as rare variants do not always behave in the same way common variants do, sometimes rendering decades of solid intuition moot. In this paper, we present examples of the differences between common and rare variants. We show why one must be significantly more careful about the origin of rare variants, and how failing to do so can lead to highly inflated type I error. We then explain how to best avoid such concerns with careful understanding and study design. Additionally, we demonstrate that a seemingly low error rate in next‐generation sequencing can dramatically impact the false‐positive rate for rare variants. This is due to the fact that rare variants are, by definition, seen infrequently, making it hard to distinguish between errors and real variants. Compounding this problem is the fact that the proportion of errors is likely to get worse, not better, with increasing sample size. One cannot simply scale their way up in order to solve this problem. Understanding these potential pitfalls is a key step in successfully identifying true associations between rare variants and diseases. 相似文献
9.
10.
Henry Havel Gregory Finch Pamela Strode Marc Wolfgang Stephen Zale Iulian Bobe Hagop Youssoufian Matthew Peterson Maggie Liu 《The AAPS journal》2016,18(6):1373-1378
Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements—only together can they realize the full potential of nanomedicines for patients. 相似文献